Institute of Dermatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, Institute of Dermatology, Università degli Studi di Pavia, Pavia, Italy.
Front Immunol. 2024 Jan 30;15:1354729. doi: 10.3389/fimmu.2024.1354729. eCollection 2024.
The aim of this study is to review the life of patients with psoriasis on biologic therapy during the SARS-CoV-2 pandemic and the relevance of frailty within this context, reviewing studies that describe the course and severity of infection in patients with psoriasis on biologics, the seroprevalence of SARS-CoV-2, and the safety and efficacy of the BNT162b2 vaccine in these patients.
The keywords "Psoriasis," "Biologics," "SARS-CoV-2," "COVID-19," and "BNT162b2 Vaccine" were used in various combinations on database engines to find relevant articles on this topic.
A total of 36 articles were found, with 20 concerning the course, severity, and seroprevalence of SARS-CoV-2 in patients with psoriasis on biologic therapy and 16 concerning safety and efficacy of BNT162b2 in these patients.
Patients with psoriasis on biologic therapy did not have increased seroprevalence compared with the general population, indicating that they were not at an increased risk of SARS-CoV-2 infection compared with the general population. Furthermore, the immunosuppressive action of biologics may be protective, as patients on biologic therapy had better outcomes and less risk of severe infection. The seroconversion rate against SARS-CoV-2 from the BNT162b2 vaccine was similar in both patients with psoriasis on biologics and the general population, indicating that efficacy is not hindered by the biologic therapy. However, the cellular response in population with psoriasis was significantly less intense, and the humoral immune response was weaker than that in the general population, demonstrating that the possibility of tighter vaccination schedules and additional doses may be advantageous in these patients.
本研究旨在回顾 COVID-19 大流行期间接受生物治疗的银屑病患者的生活，并探讨在此背景下衰弱的相关性，同时回顾描述生物制剂治疗银屑病患者感染过程和严重程度、抗 SARS-CoV-2 血清阳性率以及这些患者中 BNT162b2 疫苗安全性和有效性的研究。
在数据库引擎中使用了“银屑病”、“生物制剂”、“SARS-CoV-2”、“COVID-19”和“BNT162b2 疫苗”等关键词进行了各种组合，以找到有关该主题的相关文章。
共发现 36 篇文章，其中 20 篇涉及生物制剂治疗银屑病患者 SARS-CoV-2 的病程、严重程度和血清阳性率，16 篇涉及这些患者 BNT162b2 的安全性和有效性。
与普通人群相比，接受生物制剂治疗的银屑病患者的血清阳性率没有增加，这表明与普通人群相比，他们感染 SARS-CoV-2 的风险没有增加。此外，生物制剂的免疫抑制作用可能具有保护作用，因为接受生物制剂治疗的患者具有更好的结局和更低的严重感染风险。来自 BNT162b2 疫苗的 SARS-CoV-2 血清转化率在接受生物制剂治疗的银屑病患者和普通人群中相似，这表明生物制剂治疗不会阻碍疗效。然而，银屑病患者的细胞反应明显较弱，体液免疫反应也比普通人群弱，这表明这些患者可能需要更紧密的疫苗接种方案和额外的剂量。
